Treatment Considerations in Relapsed Refractory Multiple Myeloma

Thomas G. Martin, MD, discusses the utility of CAR T-cell therapy in late relapsed multiple myeloma.

Joseph Mikhael, MD, discusses the promise of bispecific antibodies in multiple myeloma.

Suzanne Lentzsch, MD, discusses how patient age informs treatment decisions in multiple myeloma.

Thomas G. Martin, MD, discusses the potential utility of quadruplet-based regimens in relapsed/refractory multiple myeloma.

Suzanne Lentzsch, MD, discusses the utility of cellular therapies in multiple myeloma.

Joseph Mikhael, MD, discusses treatment selection for early relapse in multiple myeloma.